Literature DB >> 19092330

A mistaken diagnosis of type 2 diabetes due to hemoglobin N-Baltimore.

Ebenezer A Nyenwe1, Joseph N Fisher.   

Abstract

Glycohemoglobin (HbA1c) estimation is the gold standard for assessing long-term glycemic control in diabetic patients. Some hemoglobin variants interfere with HbA1c assay, thus, limiting its utility. Over 150,000 diabetic patients are estimated to have hemoglobin variants in the United States; but this number may be up to 30% in some parts of the world. Although, most of the hemoglobinopathies are clinically silent, some of them cause biochemical aberrations, which could interfere with HbA1c assay. However, hemoglobin N-Baltimore has not been reported to give false HbA1c estimation. We present a woman with mistaken diagnosis of diabetes due to hemoglobin N-Baltimore that produced a spuriously elevated HbA1c level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19092330     DOI: 10.1097/MAJ.0b013e318164bcd3

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  4 in total

1.  Interference of Hemoglobin N-Baltimore on Measurement of HbA1c Using the HA-8160 and HA-8180 HPLC Methods.

Authors:  Mercedes Lorenzo-Medina; Patricia Nogueira-Salgueiro; Adys Martin-Aguila; Lidia Ruiz-Garcia
Journal:  J Diabetes Sci Technol       Date:  2015-02-23

Review 2.  Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes.

Authors:  Ebenezer A Nyenwe; Terri W Jerkins; Guillermo E Umpierrez; Abbas E Kitabchi
Journal:  Metabolism       Date:  2011-01       Impact factor: 8.694

Review 3.  The long and winding road to optimal HbA1c measurement.

Authors:  Randie R Little; Curt L Rohlfing
Journal:  Clin Chim Acta       Date:  2013-01-11       Impact factor: 3.786

4.  Led Astray by Hemoglobin A1c: A Case of Misdiagnosis of Diabetes by Falsely Elevated Hemoglobin A1c.

Authors:  Jean Chen; Amy Diesburg-Stanwood; Geza Bodor; Neda Rasouli
Journal:  J Investig Med High Impact Case Rep       Date:  2016-01-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.